NewTimeSpace News: Yueda International Holdings announced on 23 July that Yueda Commercial Factoring, its indirectly wholly-owned subsidiary, entered into a reverse factoring agreement with Dongtai Houyao on the same date, granting a revolving reverse factoring credit limit of RMB 30 million.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 23, 2026, MINIEYE(02431.HK) saw a loss of 16.78% in its share price, closing at HKD 6.1. During the session, it reached an intraday high of HKD 6.99
NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 23, 2026, EVEREST GOLD(01815.HK) saw a gain of 19.2% in its share price, closing at HKD 1.49. During the session, it reached an intraday high of HKD 1.5 and touched an intraday low of HKD 1.25.
NewTimeSpace News: Huaneng Power International disclosed via an announcement dated July 23 that the Company has completed the issuance of its 9th tranche of 2026 Medium-Term Notes (Special Bonds for Ensuring Energy Supply), with an issuance volume of RMB 2.5 billion and an issuing interest rate of 1.67%.
NewTimeSpace News: Weihai Bank(09677.HK) announced that Ms. Li Jie, Non-executive Director, will cease to act as Non-executive Director and member of relevant board committees on account of age. At the 2nd Session of the 6th Staff Congress held on 23 July 2026, Ms. Wang Wenjing was elected as employee representative Non-executive Director of the 9th Board of Directors to fill the vacancy arising from Ms. Li’s retirement.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that four pharmaceutical products of the Group have secured manufacturing approvals issued by NMPA. Classified as Category 4 chemical drugs, all are deemed to have passed generic consistency evaluation. The portfolio comprises Sodium Citrate Hemofiltration Replacement Fluid (5000ml), Benidipine Hydrochloride Tablets (4mg), 1.4% Polyvinyl Alcohol Eye Drops (0.4ml:5.6mg), and Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml & 1026ml). The approvals further enrich the Group’s product portfolio covering blood purification, hypertension, ophthalmology and parenteral nutrition.
NewTimeSpace News:CFMEE (09630.HK) announced that the stabilisation period in relation to its global offering ended on 23 July 2026. The stabilisation manager over-allotted a total of 1,925,750 offer shares in the international offering, representing approximately 15.0% of the initial offer shares available under the global offering. The over-allotment option was fully exercised on 10 July 2026. No H Shares were traded in the market for stabilisation purposes during the stabilisation period.
NewTimeSpace News: On July 23, 2026, RoboSense (02498.HK) edged down moderately in afternoon trading. As of 15:10, its intraday quotation stood at HK$22.70, a drop of 1.22%. During the World Artificial Intelligence Conference (WAIC) held in Shanghai, RoboSense unveiled successive strategic cooperation partnerships with four corporations.
NewTimeSpace (newtimespace.com) reported that on July 23, 2026, the chip theme retreated during trading, with HUA HONG GRACE (01347.HK) fluctuating lower. As of 13:30, the stock was quoted at HKD 152.200, down 5.76%.
NewTimeSpace (newtimespace.com) reported that on July 23, 2026, the robotics theme showed choppy trading, with Midea Group (00300.HK) rising in volatile trading. As of 13:14, the stock was quoted at HKD 95.600, up 0.74%.
NewTimeSpace News: Keymed Biosciences Inc. (02162.HK) announced that its key pipeline asset CM512, a TSLP/IL-13 bispecific antibody, has been included in the Breakthrough Therapy Programme by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). CM512 is the world’s first IgG-like long-acting TSLP × IL-13 dual blocker.
NewTimeSpace News: TYK Medicines，Ltd. (02410.HK) announced that it has filed a lawsuit with Changxing County People’s Court and commenced legal proceedings against Sichuan Huayu Pharmaceutical. The Company seeks judicial confirmation that the purported TY-9591 cooperation agreement and distribution agreement entered into with Huayu are not established and void. Meanwhile, the Company has received a case acceptance notice from Neijiang Shizhong District People’s Court in relation to a parallel claim initiated by Huayu. Both cases have been registered and are pending trial.
NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that preclinical data of ASC36_35 FDC, a once-monthly injectable fixed-dose co-formulation of ASC36 and ASC35, has been accepted for short oral discussion at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). Data show the candidate delivers superior weight-loss effects compared with eloralintide combined with tirzepatide in diet-induced obese (DIO) animal models.
NewTimeSpace News: Shanghai MicroPort MedBot (Group) Co., Ltd. (02252.HK) released a positive profit alert. It expects to record a net profit of approximately RMB28 million to RMB40 million for the first half of 2026, compared with a net loss of RMB115 million in the same period last year, marking its first semi-annual profit since listing. Revenue for the period is projected to surge 200%–230% year-on-year; overseas revenue of Toumai laparoscopic surgical robot jumped more than 450% YoY.
NewTimeSpace News: MEXAN (00022.HK) announced that Mr. Lun Yiu Ki has resigned as Chairman, Executive Director and Authorised Representative to focus on other business commitments, effective 22 July 2026. Executive Director Mr. Law Hok Yu has been re-appointed as Chairman of the Executive Committee. Independent Non-executive Director Ms. Chan Wai Yan is appointed as Authorised Representative.
NewTimeSpace News: EUROEYES International Eye Clinic Limited (01846.HK) announced the completion of its acquisition of a leading Dutch refractive surgery provider for an aggregate consideration of approximately EUR131 million. Upon completion, the Company holds roughly 90.31% equity interest in EuroEyes Netherlands. Meanwhile, the Board resolved to reallocate unused net proceeds of about HK$152 million, originally earmarked for clinic establishment and marketing in China, to fund acquisitions of European clinic groups.
